# Atom Bioscience and Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atom-bioscience-and-pharmaceutical-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.atombp.com
- Total disclosed funding: $181M
- Latest round: Series D (Oct 16, 2023)
- Investors on record: 14

## About

Based in Zhenjiang, China, and established in 2012, Atom Bioscience and Pharmaceutical Co., Ltd. operates as a pharmaceutical company that focuses on new drug discovery and treatments. The founder as well as the CEO, Dongfang Shi, worked at Genelabs Technologies and Metabolex. The CMO, Marc Gurwith, was the Executive Vice President of PaxVax Inc. In January 2022, the company raised CNY 300 million co-led by new investors GTJA Investment Group and Xicheng Jinrui. In October 2023, it raised over CNY 600 million in series D funding led by Kaitai Capital, with participation from Fortune Capital, Golden China Fund, Qiandao Group, and NNFE Investment Fund Management (Beijing). 

The company provides new drugs and related treatments for metabolic diseases and cancers. Its product pipelines include ABP-6016, ABP-671, ABP-745 and ABP-431. ABP-671 achieves a reduction of serum uric acid (sUA) by inhibiting renal uric acid transport protein 1 (URAT1). The drugs developed by the company can be used to treat diabetes, gout, and tumors.

## Funding rounds

- Series D, Oct 16, 2023, $82M — Fortune Capital, Kaitai Capital, Golden China Fund, NNFE, Qiandao Group
- Series C, Jan 4, 2022, $47M — Hong Shan, GTJA Investment Group, Kaitai Capital, Efung Capital, Oriza Holdings, Livzon Pharmaceutical Group Inc., Kingray Capital, Qiandao Group
- Series B, Mar 15, 2021 — Kaitai Capital
- Series B, May 27, 2020, $30M — Hong Shan, Fortune Capital, Kaitai Capital, Livzon Pharmaceutical Group Inc.
- Series B, Jan 17, 2020, $22M — Kaitai Capital, Livzon Mabpharm, Inc.
- Series A, Jun 15, 2018 — Ch-Gemstone Capital, Youchoose Capital
- Series A, Jun 22, 2017 — Kaitai Capital

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A, Series B, Series C, Series D
- Ch-Gemstone Capital — Series A
- Youchoose Capital — Series A
- Livzon Mabpharm, Inc. — Series B
- Hong Shan — Series B, Series C
- Fortune Capital — Series B, Series D
- Livzon Pharmaceutical Group Inc. — Series B, Series C
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C
- Kingray Capital (https://capitalatlas.ai/funds/kingray-capital) — Series C
- Qiandao Group — Series C, Series D
- Golden China Fund (https://capitalatlas.ai/funds/golden-china-fund) — Series D
- NNFE (https://capitalatlas.ai/funds/nnfe) — Series D